ES2184756T3 - Uso de metioninasa como agente antitumoral en quimioterapia antimetionina. - Google Patents
Uso de metioninasa como agente antitumoral en quimioterapia antimetionina.Info
- Publication number
- ES2184756T3 ES2184756T3 ES94901634T ES94901634T ES2184756T3 ES 2184756 T3 ES2184756 T3 ES 2184756T3 ES 94901634 T ES94901634 T ES 94901634T ES 94901634 T ES94901634 T ES 94901634T ES 2184756 T3 ES2184756 T3 ES 2184756T3
- Authority
- ES
- Spain
- Prior art keywords
- chemotherapy
- methioninase
- metioninase
- antimetionine
- antitumoral agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
LA PRESENTE INVENCION DESCRIBE METODOS PARA USAR METIONINASA COMO UN REACTIVO ANTITUMOR EN LA QUIMIOTERAPIA ANTIMETIONINA. ESPECIFICAMENTE, LA METIONINASA ES USADA PARA DISMINUIR O PARAR LA DIVISION DE LA CELULA QUE PUEDE SER INCREMENTADA CON INHIBIDORES COMPETITIVOS DE METIONINA. EN ADICION, LA METIONINASA PUEDE SER USADA EN COMBINACION CON AGENTES ANTIMITOTICOS PARA INCREMENTAR LA EFECTIVIDAD TERAPEUTICA DEL ANTIMITOTICO POR INDUCIR LA SINCRONIZACION DEL CICLO DE LA CELULA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97916592A | 1992-11-19 | 1992-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2184756T3 true ES2184756T3 (es) | 2003-04-16 |
Family
ID=25526753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94901634T Expired - Lifetime ES2184756T3 (es) | 1992-11-19 | 1993-11-19 | Uso de metioninasa como agente antitumoral en quimioterapia antimetionina. |
Country Status (11)
Country | Link |
---|---|
US (1) | US5690929A (es) |
EP (2) | EP0668933B1 (es) |
JP (1) | JP2930723B2 (es) |
AT (2) | ATE440615T1 (es) |
AU (1) | AU687768B2 (es) |
CA (1) | CA2149776C (es) |
DE (2) | DE69334292D1 (es) |
DK (1) | DK0668933T3 (es) |
ES (1) | ES2184756T3 (es) |
PT (1) | PT668933E (es) |
WO (1) | WO1994011535A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6461851B1 (en) | 1992-11-19 | 2002-10-08 | Anticancer, Inc. | High expression modules containing two or more tandem copies of a methioninase encoding sequence |
US5891704A (en) * | 1992-11-19 | 1999-04-06 | Anticancer, Inc. | Method to produce high levels of methioninase |
US5861154A (en) * | 1995-10-30 | 1999-01-19 | Shionogi & Co., Ltd. | Recombinant L-methionine γ-lyase |
GB9617683D0 (en) | 1996-08-23 | 1996-10-02 | Univ Glasgow | Homocysteine desulphurase |
EP0978560B1 (en) * | 1997-03-13 | 2007-01-31 | Shionogi & Co., Ltd. | Process for producing l-methionine gamma-lyase crystals |
JP3710709B2 (ja) * | 1997-08-08 | 2005-10-26 | アンチキャンサー, インコーポレイテッド | メチオニナーゼをコードする配列の2つ以上のタンデムなコピーを含有する高発現モジュール |
US5885767A (en) * | 1998-05-22 | 1999-03-23 | Biocatalytics, Inc. | Methods and compositions for quantitating L-homocysteine and/or l-methionine in a solution |
US6524571B1 (en) | 1998-10-16 | 2003-02-25 | Anticancer, Inc. | Methioninase gene therapy for tumor treatment |
WO2000067762A2 (en) | 1999-05-11 | 2000-11-16 | Anticancer, Inc. | Selenium-containing pro-drugs for cancer therapy |
US7118903B2 (en) | 2000-09-05 | 2006-10-10 | Shionogi & Co., Ltd. | L-methionine $g(g)-lyase with modified function |
WO2003020305A1 (en) * | 2001-08-30 | 2003-03-13 | Baylor College Of Medecine | Methionine restriction for cancer therapy |
US20070207158A1 (en) * | 2003-06-17 | 2007-09-06 | Harrison Roger G | Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof |
US20110002978A1 (en) | 2003-06-17 | 2011-01-06 | Harrison Roger G | Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof |
US7264819B2 (en) * | 2003-06-23 | 2007-09-04 | Anticancer, Inc. | Lyase treatment for P. carinii |
AU2004288128A1 (en) * | 2003-07-31 | 2005-05-19 | Anticancer, Inc. | The use of PLP with PEG-rMETase in vivo for enhanced efficacy |
JP4726128B2 (ja) * | 2003-12-24 | 2011-07-20 | 塩野義製薬株式会社 | タンパク質のポリマー複合体の製造方法 |
US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
US7537923B2 (en) * | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
US20110201022A1 (en) * | 2008-07-30 | 2011-08-18 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
EP2408740B1 (en) * | 2009-03-18 | 2013-11-20 | Olatec Industries LLC | Compounds for treating inflammation and pain |
CA2782444C (en) | 2010-02-04 | 2018-10-23 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof |
US20120148559A1 (en) | 2010-12-01 | 2012-06-14 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
US9200251B1 (en) | 2011-03-31 | 2015-12-01 | David Gordon Bermudes | Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith |
US9987241B2 (en) | 2014-09-25 | 2018-06-05 | The Board Of Regents Of The University Of Oklahoma | Enzyme conjugate and prodrug cancer therapy |
CN107115533A (zh) * | 2017-04-01 | 2017-09-01 | 广州华津医药科技有限公司 | 基因工程菌vnp20009‑m在制备治疗恶性肉瘤药物中的应用 |
US11446365B2 (en) | 2017-08-09 | 2022-09-20 | The Board Of Regents Of The University Of Oklahoma | Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same |
US11001826B2 (en) | 2017-10-19 | 2021-05-11 | Anticancer, Inc. | Orally administered composition to lower serum methionine levels and method of use |
CN114681598A (zh) * | 2020-12-30 | 2022-07-01 | 广州华津医药科技有限公司 | 甲硫氨酸酶在制备抗肿瘤的铁死亡诱导剂药物中的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4298590A (en) * | 1975-02-25 | 1981-11-03 | Samuel Bogoch | Detection of malignant tumor cells |
JPS5313703B2 (es) * | 1974-03-04 | 1978-05-12 | ||
JPS5352682A (en) * | 1976-10-22 | 1978-05-13 | Mitsui Toatsu Chem Inc | Purification of l-methionase |
JPS5452033A (en) * | 1977-09-29 | 1979-04-24 | Ajinomoto Co Inc | Preparation of selenoamino acid |
JPS5535049A (en) * | 1978-09-04 | 1980-03-11 | Otsuka Pharmaceut Factory Inc | Amino acid transfusion for cancerous patient |
EP0368367A1 (en) * | 1984-12-21 | 1990-05-16 | Biogen, Inc. | Purification, production and use of tumor necrosis factors |
JPH0797997B2 (ja) * | 1988-04-28 | 1995-10-25 | 帝人株式会社 | 新規生理活性ポリペプチド |
-
1993
- 1993-11-19 PT PT94901634T patent/PT668933E/pt unknown
- 1993-11-19 CA CA002149776A patent/CA2149776C/en not_active Expired - Fee Related
- 1993-11-19 DE DE69334292T patent/DE69334292D1/de not_active Expired - Lifetime
- 1993-11-19 EP EP94901634A patent/EP0668933B1/en not_active Expired - Lifetime
- 1993-11-19 AT AT02076487T patent/ATE440615T1/de not_active IP Right Cessation
- 1993-11-19 EP EP02076487A patent/EP1287830B1/en not_active Expired - Lifetime
- 1993-11-19 AU AU56154/94A patent/AU687768B2/en not_active Ceased
- 1993-11-19 JP JP6512514A patent/JP2930723B2/ja not_active Expired - Lifetime
- 1993-11-19 WO PCT/US1993/011311 patent/WO1994011535A1/en active IP Right Grant
- 1993-11-19 DK DK94901634T patent/DK0668933T3/da active
- 1993-11-19 DE DE69332357T patent/DE69332357T2/de not_active Expired - Lifetime
- 1993-11-19 AT AT94901634T patent/ATE225403T1/de not_active IP Right Cessation
- 1993-11-19 ES ES94901634T patent/ES2184756T3/es not_active Expired - Lifetime
- 1993-11-19 US US08/424,300 patent/US5690929A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69332357T2 (de) | 2003-06-18 |
PT668933E (pt) | 2003-02-28 |
EP0668933B1 (en) | 2002-10-02 |
EP1287830B1 (en) | 2009-08-26 |
ATE225403T1 (de) | 2002-10-15 |
DE69334292D1 (de) | 2009-10-08 |
JP2930723B2 (ja) | 1999-08-03 |
DK0668933T3 (da) | 2003-02-10 |
AU687768B2 (en) | 1998-03-05 |
AU5615494A (en) | 1994-06-08 |
EP0668933A1 (en) | 1995-08-30 |
EP0668933A4 (en) | 1997-05-21 |
ATE440615T1 (de) | 2009-09-15 |
JPH08507287A (ja) | 1996-08-06 |
DE69332357D1 (de) | 2002-11-07 |
US5690929A (en) | 1997-11-25 |
WO1994011535A1 (en) | 1994-05-26 |
EP1287830A1 (en) | 2003-03-05 |
CA2149776A1 (en) | 1994-05-26 |
CA2149776C (en) | 2008-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2184756T3 (es) | Uso de metioninasa como agente antitumoral en quimioterapia antimetionina. | |
ES2170252T3 (es) | Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde. | |
CY1105788T1 (el) | Χρηση του taci σαν παραγοντα καταπολεμησης ογκων | |
ES2071484T3 (es) | Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral. | |
DE69427862T2 (de) | K-252a derivate, die neurotrophin-induzierte aktivität erhöhen | |
GR74701B (es) | ||
BRPI0506977A (pt) | composto de tetrahidrocarbolina como agentes anticáncer | |
ES2000015T3 (es) | Superficies polimericas modificadas y metodo de preparacion de las mismas. | |
EP0211354A3 (en) | Nucleosides and their use as antineoplastic agents | |
ES2036553T3 (es) | Composiciones farmaceuticas que tienen actividad antineoplastica. | |
EE200200107A (et) | Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks | |
MX9400434A (es) | Potenciamiento de temozolomida en celulas de tumores humanos. | |
DE3887151D1 (de) | Inhibitoren für zellenzuwachs und methoden für krebsbehandlung. | |
ES2079068T3 (es) | 2-amino-6-fenil-4h-piran-4-onas antiateroscleroticas y antitromboticas. | |
AR219561A1 (es) | Procedimiento para la preparacion de nuevos derivados de 1-piperidino-6,7-dialcoxi-ftalazina utiles como agentes terapeuticos | |
AR218071A1 (es) | Procedimiento para mejorar el aroma y la espumosidad de vinos espumantes de diversos tipos,inclusive el champana y el vino asi tratados | |
ES2180729T3 (es) | Tratamiento terapeutico combinado de las patologias hiperproliferantes. | |
MX148281A (es) | El nuevo uso industrial de la celulosa cationicamente modificada como agente depurador de aguas residuales industriales | |
AR228596A1 (es) | 9-(2-cianoetil)-9-carbamoil-fluorenos,exentos de aplicaciones terapeuticas y utiles como intermediarios para preparar 9-carbamoil-9-amino-propil-fluorenos | |
BR0009194A (pt) | Composição do resorcinol | |
ES2053942T3 (es) | Empleo de aductos de oxido de 1,2-butileno en compuestos organicos h-azidas como lubricantes y lubricantes que contienen estos aductos. | |
ES2196171T3 (es) | Agentes antitumorales de tioxantenona liofilizada. | |
ES2056876T3 (es) | Compuestos piperidinilicos 1,4-disustituidos. | |
DE3368199D1 (en) | Mixture comprising a central analgesic and vitamin b12, or one of its analogs, as active principles | |
JPS5282676A (en) | Gas adsorption equipment of moving bed type |